Arvinas has announced the selection of its first candidate for clinical development as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC).

ARV-110 is an orally bioavailable small molecule PROTAC (PROteolysis TArgeting Chimera) designed to target and induce the degradation of the androgen receptor (AR) protein, which plays a prominent role in the development of mCRPC.

more